Table 1.

Patient Characteristics, Tumor Stage, Tumor Grade, Tumor Type, and Biomarker Status (n = 106)

Characteristic	Value
Age (y), median (range)	67 (48–89)
ECOG performance status, n (%)
0	78 (74)
1	22 (21)
2	6 (6)
Ethnicity, n (%)
Caucasian	74 (70)
African American	24 (23)
Hispanic	6 (5)
Asian	1 (1)
Unknown	1 (1)
Clinical tumor size (cm), median (range)	4.9 (2.3–12.0)
T stage, n (%)
T2	56 (53)
T3	39 (37)
T4	11 (10)
N stage, n (%)
N0	66 (62)
N1	34 (32)
N2	6 (6)
Tumor type, n (%)
Ductal	59 (56)
Lobular	25 (24)
Mixed	18 (17)
Other†	4 (4)
Tumor grade, n (%)
1	21 (20)
2	58 (55)
3	27 (25)
Biomarker status, n (%)
ER+PgR+	75 (71)
ER+PgR−	30 (28)
ER−PgR+	1 (1)
HER2-negative	97 (91.5)
HER2-positive	8 (7.6)
HER2 unknown	1 (0.9)

Nine patients excluded from analysis because of withdrawal of consent (n = 7), ineligible (n = 1), and death unrelated to disease (n = 1).

^†Mucinous, 2 (2%); tubular, 1 (1%); papillary, 1 (1%).

ECOG, Eastern Cooperative Oncology Group performance status; ER, estrogen receptor; PgR, progesterone receptor.